vs
Side-by-side financial comparison of HEALTHY CHOICE WELLNESS CORP. (HCWC) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $18.7M, roughly 1.0× HEALTHY CHOICE WELLNESS CORP.). HEALTHY CHOICE WELLNESS CORP. runs the higher net margin — -8.9% vs -90.7%, a 81.8% gap on every dollar of revenue. HEALTHY CHOICE WELLNESS CORP. produced more free cash flow last quarter ($-927.1K vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
HCWC vs NAMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $19.1M |
| Net Profit | $-1.7M | $-17.4M |
| Gross Margin | 39.1% | — |
| Operating Margin | -7.6% | -186.1% |
| Net Margin | -8.9% | -90.7% |
| Revenue YoY | — | 740.1% |
| Net Profit YoY | — | 55.5% |
| EPS (diluted) | $-0.05 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.7M | — | ||
| Q3 25 | $19.0M | — | ||
| Q2 25 | $20.2M | $19.1M | ||
| Q1 25 | $20.3M | — | ||
| Q4 24 | — | $12.8M | ||
| Q3 24 | $18.2M | $29.1M | ||
| Q2 23 | — | $8.6M |
| Q4 25 | $-1.7M | — | ||
| Q3 25 | $-1.2M | — | ||
| Q2 25 | $-339.4K | $-17.4M | ||
| Q1 25 | $-712.4K | — | ||
| Q4 24 | — | $-92.2M | ||
| Q3 24 | $-2.7M | $-16.6M | ||
| Q2 23 | — | $-42.0M |
| Q4 25 | 39.1% | — | ||
| Q3 25 | 38.8% | — | ||
| Q2 25 | 40.1% | — | ||
| Q1 25 | 38.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 23 | — | — |
| Q4 25 | -7.6% | — | ||
| Q3 25 | -3.2% | — | ||
| Q2 25 | -0.2% | -186.1% | ||
| Q1 25 | -2.0% | — | ||
| Q4 24 | — | -338.5% | ||
| Q3 24 | -2.0% | -85.9% | ||
| Q2 23 | — | -461.8% |
| Q4 25 | -8.9% | — | ||
| Q3 25 | -6.4% | — | ||
| Q2 25 | -1.7% | -90.7% | ||
| Q1 25 | -3.5% | — | ||
| Q4 24 | — | -721.7% | ||
| Q3 24 | -14.6% | -57.2% | ||
| Q2 23 | — | -486.9% |
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.03 | $-0.15 | ||
| Q1 25 | $-0.07 | — | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | $-0.29 | $-0.18 | ||
| Q2 23 | — | $-0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $739.2M |
| Total DebtLower is stronger | $7.3M | — |
| Stockholders' EquityBook value | $7.3M | $778.5M |
| Total Assets | $33.5M | $815.1M |
| Debt / EquityLower = less leverage | 1.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | — | ||
| Q3 25 | $3.0M | — | ||
| Q2 25 | $4.7M | $739.2M | ||
| Q1 25 | $1.8M | — | ||
| Q4 24 | — | $834.2M | ||
| Q3 24 | $1.8M | $422.7M | ||
| Q2 23 | — | — |
| Q4 25 | $7.3M | — | ||
| Q3 25 | $8.5M | — | ||
| Q2 25 | $9.7M | — | ||
| Q1 25 | $10.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $11.6M | — | ||
| Q2 23 | — | — |
| Q4 25 | $7.3M | — | ||
| Q3 25 | $5.9M | — | ||
| Q2 25 | $5.8M | $778.5M | ||
| Q1 25 | $2.1M | — | ||
| Q4 24 | — | $757.5M | ||
| Q3 24 | $2.9M | $378.9M | ||
| Q2 23 | — | $398.4M |
| Q4 25 | $33.5M | — | ||
| Q3 25 | $33.7M | — | ||
| Q2 25 | $36.4M | $815.1M | ||
| Q1 25 | $34.1M | — | ||
| Q4 24 | — | $864.6M | ||
| Q3 24 | $33.2M | $439.2M | ||
| Q2 23 | — | — |
| Q4 25 | 1.00× | — | ||
| Q3 25 | 1.43× | — | ||
| Q2 25 | 1.69× | — | ||
| Q1 25 | 5.01× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.95× | — | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-855.1K | $-37.7M |
| Free Cash FlowOCF − Capex | $-927.1K | $-37.8M |
| FCF MarginFCF / Revenue | -5.0% | -197.2% |
| Capex IntensityCapex / Revenue | 0.4% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $675.4K | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-855.1K | — | ||
| Q3 25 | $-308.7K | — | ||
| Q2 25 | $1.1M | $-37.7M | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.5M | ||
| Q2 23 | — | $-31.9M |
| Q4 25 | $-927.1K | — | ||
| Q3 25 | $-351.3K | — | ||
| Q2 25 | $988.6K | $-37.8M | ||
| Q1 25 | $965.3K | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 23 | — | $-31.9M |
| Q4 25 | -5.0% | — | ||
| Q3 25 | -1.8% | — | ||
| Q2 25 | 4.9% | -197.2% | ||
| Q1 25 | 4.8% | — | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 23 | — | -369.3% |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.4% | 0.5% | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 23 | — | 0.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCWC
| Retail Grocery | $17.1M | 91% |
| Food Service Restaurant | $1.7M | 9% |
NAMS
Segment breakdown not available.
